Tau-Targeting Deal Benchmarks in Neurology

Tau-Targeting therapies in neurology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 tau-targeting asset in neurology is $464M, with total deal values reaching $4.1B. Development milestones average $1.2B, while regulatory milestones contribute $1.3B.

The neurology tau-targeting landscape is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones, reflecting the risk-reward profile at the Phase 2 stage.